ADVANCED HEPATOCELLULAR CARCINOMA

This study tests whether adding celecoxib (a painkiller) to standard immunotherapy drugs (durvalumab and tremelimumab) can help control advanced liver cancer that has spread. About 39 adults with advanced or metastatic hepatocellular carcinoma will receive the combination. The go…

This early-phase study tests a new treatment called CNCT19, which uses a patient's own immune cells modified to target cancer. It is for people with advanced hepatocellular carcinoma who cannot have surgery or other local treatments. The main goals are to check safety, find the b…

This early-phase study tests a new drug called BGB-B2033, alone or with other cancer medicines, in people with advanced liver, stomach, lung, or rare germ cell tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Abo…

This early-stage study tests a new drug called ALN-BCAT, given alone or with an immunotherapy (pembrolizumab), in people with advanced liver cancer that has spread. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 158 adults whose …

This early-stage trial tests a new drug called AU409 in about 36 adults with advanced liver cancer or other cancers that have spread to the liver. The main goals are to find the safest dose and see if the drug can shrink tumors or stop them from growing. Participants must have tr…

This early-phase study tests a wearable device that creates low-intensity electric fields to disrupt cancer cell growth, combined with standard drugs (cabozantinib or nab-paclitaxel plus atezolizumab). About 43 adults with advanced solid tumors in the abdomen or chest that have s…

This study is for people with advanced liver cancer that has spread to nearby blood vessels. It compares standard immunotherapy drugs alone versus immunotherapy plus a precise, high-dose form of radiation called SBRT. The goal is to see if adding radiation helps patients live lon…

This study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific change in the β-catenin gene. The goal is to see if the combination is safe and works better than cabozantinib alone. About 92 adults with liver cancer tha…

This study tests a new medicine, PF-08634404, given alone or with another drug (ipilimumab) for adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if the treatment is safe and shrinks tumors. About 138 participants will receive the drug throug…

This study tests whether adding immunotherapy drugs (durvalumab with or without tremelimumab) after standard radiation therapy can help control advanced liver cancer that has spread. About 21 adults whose cancer has worsened despite prior treatment will receive radiation followed…

This study tests whether two drugs, ligufalimab and cadonilimab, can shrink advanced liver or bile duct cancers that have stopped responding to standard treatments. About 64 adults will receive the drug combination to see if tumors get smaller. The goal is to find a new option fo…

This study tests a new three-drug combination (SHR-8068, adebrelimab, and bevacizumab) against standard two-drug treatments for advanced liver cancer that cannot be removed by surgery. About 590 adults with this type of cancer will participate. The goal is to see if the new combo…

This study tests a drug called ADI-PEG 20 against a placebo in 300 people with advanced liver cancer that cannot be removed by surgery and who have high levels of the amino acid arginine in their blood. The goal is to see if the drug helps people live longer. Participants must ha…

This study compares giving cancer treatment at home versus in a clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves the overall experience. About 220 participants will be randomly assigned to receive their t…

This study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…